Treatment Advancements to Overcome Barriers in the Management of Schizophrenia: Key Considerations for Pharmacists

This activity was originally broadcast live at the CPNP 2022 Annual Meeting.

Program Description

Clinical consequences associated with uncontrolled symptoms of schizophrenia present treatment challenges and can increase disease burden for both patients and health care providers. Recognizing treatment challenges, including nonadherence to therapy or suboptimal therapy, and identifying potential strategies to improve adherence are essential to prevent disease relapse and improve overall patient outcomes. Pharmacists have an important role in the treatment of schizophrenia by helping to choose initial therapy according to patient-specific factors, addressing suboptimal therapeutic responses, and mitigating adverse effects. The current treatment landscape of schizophrenia continues to evolve with novel therapies and routes of administration, offering pharmacists more opportunities to make treatment interventions to improve patients’ symptom control, improve adherence, and address treatment-related challenges. This program will review updated clinical guidelines, efficacy and safety of newer treatment strategies, and considerations for their administration in both inpatient and outpatient clinical practice settings.

Target audience: Health-system pharmacists, retail pharmacists, and specialty pharmacists

Type of activity: Application
Release date: May 17, 2022
Expiration date: May 17, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the current and emerging data on the disease burden and progression of schizophrenia
• Discuss current evidence-based guidelines, newly emerging agents, and therapeutic challenges in schizophrenia
• Identify the role of the pharmacist in addressing treatment challenges in schizophrenia, including patient education and optimizing adherence

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-254-H01-P. The activity is available for CE credit through May 17, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Megan Maroney, PharmD, BCPP, has the following relevant financial relationships with commercial interests to disclose:

Consultant – Novus Medical Education

Speakers Bureau – Otsuka Pharmaceuticals

Advisory Board – Sunovion Pharmaceuticals, Boehringer Ingelheim

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa-Buszka, PharmD, BCPS; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms